Skip to main navigation Skip to search Skip to main content

Fibrosis on a chip for screening of anti-fibrosis drugs

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

4 Scopus citations

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic pathological disorder that targets alveoli interstitial tissues and is characterized by the progressive stiffening of alveolar membrane. The median survival rate of the patients with IPF is less than 5 years. Currently, IPF has no cure and there are few options to alleviate the progress of this disease. A critical roadblock in developing new anti-fibrosis therapies is the absence of reliable cell based in vitro models that can recapitulate the progressive features of this disease. Here a novel fibrotic microtissue on a chip system is created to model the fibrotic transition of the lung interstitial tissue and the effect of anti-fibrosis drugs on such transitions. This system will not only help to expedite the efficacy analysis of anti-fibrotic therapies but also help to unveil their potential mode of action.

Original languageEnglish
Title of host publicationMethods in Molecular Biology
PublisherHumana Press Inc.
Pages263-274
Number of pages12
DOIs
StatePublished - 2021

Publication series

NameMethods in Molecular Biology
Volume2299

Keywords

  • Anti-fibrosis therapy
  • Drug screening
  • Lung on a chip
  • Microtissue array
  • Nintedanib
  • Pirfenidone
  • Pulmonary fibrosis
  • Stiffness, and contractile force
  • Tissue mechanics

Fingerprint

Dive into the research topics of 'Fibrosis on a chip for screening of anti-fibrosis drugs'. Together they form a unique fingerprint.

Cite this